Category: Business

EYE TECH CARE宣佈與中國投資者達成重要的注資和夥伴關係協定

法國里昂–(BUSINESS WIRE)–(美國商業資訊) — EYE TECH CARE SA是開發和行銷非侵入性青光眼治療眼科醫療器材的公司,該公司今天宣佈已獲得一家中國投資者的新一輪注資。恒松資本將分兩輪投資,總金額約為2500萬歐元,並將支持EYE TECH CARE的國際擴張。該公司將受益於恒松資本在中國大陸的佈局,從而推動已經於2015年啟動的產品報批。 中國大陸是該公司的主要市場:中國大陸有2200萬名青光眼患者,占全世界青光眼患者的28% (MarketScope 2014)。但由於治療水準相對較低,僅有6%左右的中國大陸患者獲得治療。多數青光眼患者屬於晚期,常需要使用複雜的治療手段。在此背景下,EYE TECH CARE開發的非侵入性治療可提供替代性解決方案,完美迎合中國大陸市場的需求。 這家法國公司開發的創新醫療器材EyeOP1®使用超音波來治療青光眼,為青光眼治療提供使用簡便的非侵入性解決方案。UCP手術(超音波睫狀體成形術)是唯一針對未獲控制的青光眼而開發的醫療手術,無論患者以往是否接受過治療。 EYE TECH CARE執行長Dietrich Wolf


EYE TECH CARE宣布与中国投资者达成一项重要的注资和伙伴关系协议

法国里昂–(BUSINESS WIRE)–(美国商业资讯) — EYE TECH CARE SA是一家开发和营销青光眼无创治疗眼科医疗器材的公司,该公司今天宣布已获得一家中国投资者的新一轮注资。恒松资本将分两轮投资,总金额约为2500万欧元,并将支持EYE TECH CARE的国际扩张。公司将受益于恒松资本在中国的布局,从而推进已经于2015年启动的产品报批。 中国是该公司的主要市场:中国有2200万青光眼患者,占世界青光眼患者的28% (MarketScope 2014)。但由于治疗水平相对较低,仅有6%左右的中国患者获得治疗。多数青光眼患者属于晚期,常需要使用复杂的治疗手段。在此背景下,EYE TECH CARE开发的无创治疗可提供替代性解决方案,完美符合中国市场的需求。 这家法国公司开发的创新医疗器材EyeOP1®为青光眼超声治疗提供了一个使用简便的无创解决方案。UCP手术(超声睫状体成形术)是唯一针对未获控制的青光眼而开发的医疗手术,无论患者既往是否接受过治疗。 EYE TECH CARE首席执行官Dietrich Wolf先生说:“我们很高兴地欢迎恒松资本成为公司的财


Bruker Presentation at the 34th Annual J.P. Morgan Healthcare Conference to be Webcast Live

BILLERICA, Mass.–(BUSINESS WIRE)–Bruker (NASDAQ: BRKR) today announced that it will webcast its presentation to the investment community at the J.P. Morgan Healthcare Conference on Monday, January 11, 2016, at 1:30 p.m. Pacific Time. To listen to the live webcast, investors can go to http://ir.bruker.com and click on the “Events and Presentations” hyperlink to access the webcast. About Bruker Corporation For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries an


NovaBay Pharmaceuticals Secures $3 Million Bridge Loan

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova® Lid and Lash Cleanser for the domestic eye care market, announces that it has secured a $3 million bridge loan. NovaBay has already received approximately $1.66 million, with the remaining approximate $1.37 million to be funded later this month. The loan has a three-year term with no pre-payment penalty. The loan, managed by China Kington Asse


Research and Markets: US & Europe Corneal Topographers Market Report – Analysis, Technologies & Forecasts 2016-2020

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/zcs6hd/us_and_europe) has announced the addition of the “US & Europe Markets for Corneal Topographers – 16 Countries (2010-2020)” report to their offering. The US & Europe Markets for Slit Lamps covers 16 Countries and includes detailed and comprehensive information and data on Pacido Ring Corneal Topographers as well as Scheimpflug cameras. Corneal topography is also known as videokeratography or


Ocata Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (OCAT), a leader in the field of regenerative medicine, reported today that early research was published in the journal PLOS One (online, December 21, 2015) by Ocata and its collaborators at the University of Miami, UCSD, and Stanford University. The publication presents a method for generating scalable amounts of human embryonic stem cell derived corneal endothelial cells (hESC-CEC). “Disease and injury to the cornea are leading cau